Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy - an update.

Autor: Le Hars M; UMR U1179 INSERM - University of Versailles Saint Quentin en Yvelines (UVSQ)-Paris Saclay, Montigny-le-Bretonneux, France., Joussain C; UMR U1179 INSERM - University of Versailles Saint Quentin en Yvelines (UVSQ)-Paris Saclay, Montigny-le-Bretonneux, France., Jégu T; EG 427 SAS, Paris, France., Epstein AL; EG 427 SAS, Paris, France. alberto@eg427.com.
Jazyk: angličtina
Zdroj: Gene therapy [Gene Ther] 2024 Nov 12. Date of Electronic Publication: 2024 Nov 12.
DOI: 10.1038/s41434-024-00500-x
Abstrakt: Two major types of defective vectors have been derived from herpes simplex virus type 1 (HSV-1), non-replicative genomic vectors (nrHSV-1), and amplicon vectors. This review recapitulates the main features of both vector types and summarizes recent improvements in our understanding of virus/vector biology, particularly with regard to the critical role played by the overpowering of antiviral cellular defenses and the epigenetic control of viral gene expression. Over the past years, significant breakthroughs in vector design, genetic engineering, and HSV-1 biology have accelerated the development of nrHSV-1 vectors. The low immunogenicity and enhanced safety profiles allowed the successful translation of these vectors into several clinical trials, with some being approved by the FDA. Regarding amplicons, despite their advantage in carrying very large or multiple transgenes, and their potential to avoid genome dilution in dividing cells, the absence of production procedures capable of generating large amounts of helper-free amplicons at reasonable cost with GMP compliance, still limits the translation of these outstanding vectors to clinical trials.
Competing Interests: Competing interests ALE, TJ, and CJ are shareholders of EG 427. ALE is the chief scientific officer (CSO) of EG 427 while TJ is the director of the R&D platform of EG 427. ALE and TJ are co-inventors on patents related to the use of replication-incompetent herpes simplex virus-based vectors, owned by the University of Versailles Saint Quentin (France) and EG 427.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: